Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 71 to 80 of 220 total matches.

Adagrasib (Krazati) for Colorectal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Adagrasib is the first KRAS inhibitor ...
The RAS GTPase family inhibitor adagrasib (Krazati – BMS), which received accelerated approval for treatment of KRAS G12C (glycine-to-cysteine mutation at codon 12)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2022, has now received accelerated approval from the FDA for use with cetuximab for treatment of KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) in adults who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Adagrasib is the first KRAS inhibitor to be approved in the US for treatment...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e137-8   doi:10.58347/tml.2024.1709f |  Show IntroductionHide Introduction

Temozolomide for Refractory Anaplastic Astrocytoma

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999  (Issue 1068)
gliomas is surgical resection followed by cranial irradiation. Further treatment with chemotherapy ...
Temozolomide has received accelerated approval from the FDA for oral treatment of adults with anaplastic astrocytoma that has relapsed after treatment with a nitrosourea (lomustine or carmustine) and procarbazine.
Med Lett Drugs Ther. 1999 Dec 17;41(1068):123-4 |  Show IntroductionHide Introduction

Bortezomib (Velcade) for Multiple Myeloma

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2003  (Issue 1161)
steroids, chemotherapy and stem cell transplantation (A Kumar et al, Lancet Oncol 2003; 4:293). None ...
Bortezomib (PS341; Velcade Millenium), the first proteasome inhibitor, has received accelerated approval from the FDA for treatment of refractory multiple myeloma. This review includes descriptions of the mechanism of action, pharmacokinetics, adverse effects, and dosage and cost of bortezomib, outlines the results of clinical studies, and concludes with an overall assessment of the drug's effectiveness.
Med Lett Drugs Ther. 2003 Jul 21;45(1161):57-68 |  Show IntroductionHide Introduction

Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
Besponsa: beh spon’ suh RELAPSED OR REFRACTORY ALL — Induction chemotherapy induces a complete remission ...
The FDA has approved inotuzumab ozogamicin (Besponsa – Pfizer), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It is the first CD22-directed antibody-drug conjugate to be approved in the US.
Med Lett Drugs Ther. 2018 May 21;60(1547):e90-1 |  Show IntroductionHide Introduction

In Brief: Brentuximab Vedotin (Adcetris) for Classical Hodgkin's Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
in combination with chemotherapy for IV treatment of adults with previously untreated stage 3 or 4 classical ...
The FDA has approved the anti-CD30 antibody-drug conjugate brentuximab vedotin (Adcetris – Seattle Genetics) for use in combination with chemotherapy for IV treatment of adults with previously untreated stage 3 or 4 classical Hodgkin's lymphoma (cHL). Adcetris was approved earlier for consolidation treatment of cHL and for treatment of relapsed or refractory cHL, anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.FDA approval for the new indication was based on the results of an open-label trial (ECHELON-1) in 1334 patients with previously untreated stage 3 or 4 cHL.1...
Med Lett Drugs Ther. 2018 Nov 5;60(1559):e185 |  Show IntroductionHide Introduction

Erythropoietin (Procrit; Epogen) Revisited

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
to chronic renal failure, cancer chemotherapy or HIV treatment, and before elective non-cardiac surgery ...
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA for treatment of anemia due to chronic renal failure, cancer chemotherapy or HIV treatment, and before elective non-cardiac surgery. It is also used illicitly by competitive athletes to increase their endurance.
Med Lett Drugs Ther. 2001 May 14;43(1104):40-1 |  Show IntroductionHide Introduction

Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002  (Issue 1144)
. Standard therapy has included conventional external radiation and chemotherapy. Most recently ...
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab (Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer.
Med Lett Drugs Ther. 2002 Nov 25;44(1144):101-2 |  Show IntroductionHide Introduction

Tisagenlecleucel (Kymriah) for ALL

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
. About 80% of children respond to first-line chemotherapy, but if leukemia recurs, it is less ...
The FDA has approved tisagenlecleucel (Kymriah — Novartis), an individualized, genetically-modified cellular product, for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old. The patient's own T cells are genetically modified to express chimeric antigen receptors (CAR) and then reinfused. Kymriah is the first CAR T-cell immunotherapy to become available in the US. A CAR T-cell product for B-cell non-Hodgkin's lymphoma is expected to be approved soon.
Med Lett Drugs Ther. 2017 Oct 23;59(1532):177-8 |  Show IntroductionHide Introduction

Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
of non-Hodgkin lymphoma, respond to chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine ...
The FDA has approved axicabtagene ciloleucel (Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell...
Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-3 |  Show IntroductionHide Introduction

Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
lymphodepleting chemotherapy (fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2, both IV once daily for 3 days ...
The FDA has approved idecabtagene vicleucel (Abecma – BMS), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Abecma is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Ciltacabtagene autoleucel...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e190-1 |  Show IntroductionHide Introduction